Business Wire

MA-BRIGHTCOVE

2.12.2021 15:02:14 CET | Business Wire | Press release

Share
ENTERPRISE AND MEDIA ORGANIZATIONS DRIVE REVENUE, ENGAGEMENT, AND DEMAND WITH BRIGHTCOVE SOLUTIONS, INDEPENDENT STUDY REVEALS

Brightcove Inc. (Nasdaq: BCOV), the global leader in video for business, released findings that enterprises and media organizations can generate 225% and 226% ROI respectively with Brightcove and see a full return on the initial investment in less than six months. The commissioned Total Economic Impact™ (TEI) studies conducted by Forrester Consulting examined cost savings and business benefits with Brightcove solutions for enterprise and media organizations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005560/en/

Forrester Consulting interviewed decision-makers at multiple enterprise and media organizations with experience using Brightcove. Respondents came from organizations headquartered in the US and EMEA, all with multi-billion dollars of annual revenues. The enterprise interviewees represented industries including automotive manufacturing, technology manufacturing, and media services that primarily use video to sell products and services and train their employees. The media organizations’ interviewees represented decision-makers at media organizations already using Brightcove to stream and monetize their content.

Enterprise ROI

The study found that after the investment in Brightcove, the interviewees’ organizations gained increased insights, reduction in management and distribution time of content, and most importantly increased digital engagement. Decision-makers who deployed the videos hosted by the Brightcove platform in conjunction with revenue-generating offerings found that their organization could use the analytics Brightcove provided to adapt their content to meet the needs of their different audiences whether employees, customers, or partners. Prior to using Brightcove, enterprises had disjointed video management solutions and workflows and strived for improved analytics, the ability to scale content, and syndicate videos for distribution to any source.

One platform product manager in the technology manufacturing sector cited Brightcove’s user experience and easy-to-use interface as considerably better than their previous video provider's solution. Their team realized they could globalize videos more quickly with multilingual metadata, whereas before the team needed to manually change titles, thumbnails, and subtitles. As part of an organization that operates in 27 locales, the team now spends less time on manually translating videos, and more time focusing on high-value workflows, such as content creation and campaign strategy.

Multiple users cited the benefits of Brightcove’s user experience and easy-to-use interface, the business impact of which includes savings on resource expenditure through content management efficiencies including:

  • 80% reduction in time it takes to migrate content with advanced processing power
  • 83% reduction in time spent on manual content management tasks
  • 50% reduction in spend for additional content distribution and management
  • 75% reduction in video syndication time

Media ROI

As media organizations search for ways to expand their offerings globally, there is an increased need for superior video quality, faster time to market, and ways to monetize their content. The study found that media customers that use the Brightcove platform can better distribute and monetize live and on-demand video content on multiple platforms more securely and reliably. Prior to using Brightcove, media organizations missed expansion opportunities due to technical complexities like slow transcoding times, failure and downtime during peak demand, and time-consuming quality assurance processes.

With Brightcove’s platform, media organizations are able to expand more easily to new markets and devices through faster transcoding of content, more reliable content processing, and improved end-viewer experiences resulting in increased customer lifetime values.

A global head of media technology at a media/entertainment organization, commented on Brightcove’s constant technology enhancements, resulting in better quality with more bandwidth. After switching from their legacy solution to Brightcove, they noticed a significant increase in quality for their audiences.

Other key outcomes for media organizations include:

  • 15-25% increase in potential audience over modeled period
  • 80% reduction in time to migrate content to improve ability to scale
  • 83% reduction in time spent on manual content management tasks
  • 75% reduction in the number of compliance violations

“Companies know that video is THE most effective way of connecting with their audiences. Too frequently, however, companies have not been able to quantify the business benefits or even know what metrics they should be targeting to improve,” said Jennifer Griffin Smith, CMO, Brightcove. “Forrester’s findings provide guidance into the key areas of opportunity for our customers including improved user engagement, increased audience acquisition, new market expansion, and revenue generation. It also highlights, in our opinion, the experience we have at Brightcove in helping companies scale their operations more effectively and measure business impact.”

To read the Forrester Total Economic Impact™ study, visit https://www.brightcove.com/en/resources/downloads/studies/forrester-tei-study/

About Brightcove Inc.

Brightcove creates the world’s most reliable, scalable, and secure video technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 70 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow Brightcove on Twitter , LinkedIn , and Facebook . Visit www.brightcove.com . Brightcove. Video that means business™.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye